World Journal of *Clinical Cases*

World J Clin Cases 2023 February 16; 11(5): 979-1223





Published by Baishideng Publishing Group Inc

W J C C World Journal of Clinical Cases

Contents

Thrice Monthly Volume 11 Number 5 February 16, 2023

MINIREVIEWS

- 979 Non-clostridium difficile induced pseudomembranous colitis Jagirdhar GSK, Surani S
- 989 Pleural effusion in critically ill patients and intensive care setting Bediwy AS, Al-Biltagi M, Saeed NK, Bediwy HA, Elbeltagi R

ORIGINAL ARTICLE

Retrospective Study

1000 Investigation of litigation in trauma orthopaedic surgery Salimi M, Heidari MB, Ravandi Z, Mosalamiaghili S, Mirghaderi P, Jafari Kafiabadi M, Biglari F, Salimi A, Sabaghzadeh Irani A, Khabiri SS

1009 Type 2 diabetes mellitus characteristics affect hepatocellular carcinoma development in chronic hepatitis B patients with cirrhosis

Li MY, Li TT, Li KJ, Zhou C

- 1019 Relationship between glycemic variability and cognitive function in lacune patients with type 2 diabetes Meng QZ, Wang Y, Li B, Xi Z, Wang M, Xiu JQ, Yang XP
- 1031 COVID-19-related cardiomyopathy: Can dual-energy computed tomography be a diagnostic tool? Aydin F, Kantarci M, Aydın S, Karavaş E, Ceyhun G, Ogul H, Şahin ÇE, Eren S

Observational Study

Multiple regression analysis of risk factors related to radiation pneumonitis 1040 Shi LL, Yang JH, Yao HF

- 1049 Right hemicolectomy combined with duodenum-jejunum Roux-en-Y anastomosis for hepatic colon carcinoma invading the duodenum: A single-center case series Liu PG, Feng PF, Chen XF
- Analysis of the value and safety of thyroid-stimulating hormone in the clinical efficacy of patients with 1058 thyroid cancer

Liang JJ, Feng WJ, Li R, Xu RT, Liang YL

CASE REPORT

1068 Effect of liver transplantation with primary hyperoxaluria type 1: Five case reports and review of literature Wang XY, Zeng ZG, Zhu ZJ, Wei L, Qu W, Liu Y, Tan YL, Wang J, Zhang HM, Shi W, Sun LY

1077 Diagnosis of an intermediate case of maple syrup urine disease: A case report Lin YT, Cai YN, Ting TH, Liu L, Zeng CH, Su L, Peng MZ, Li XZ



Conton	World Journal of Clinical Cas Contents Thrice Monthly Volume 11 Number 5 February 16, 202	
Conten		
1086	Angioimmunoblastic T-cell lymphoma induced hemophagocytic lymphohistiocytosis and disseminated intravascular coagulopathy: A case report	
	Jiang M, Wan JH, Tu Y, Shen Y, Kong FC, Zhang ZL	
1094	Giant myxofibrosarcoma of the esophagus treated by endoscopic submucosal dissection: A case report	
	Wang XS, Zhao CG, Wang HM, Wang XY	
1099	Novel gene mutation in maturity-onset diabetes of the young: A case report	
	Zhang N, Zhao H, Li C, Zhang FZ	
1106	Orthodontic-surgical treatment for severe skeletal class II malocclusion with vertical maxillary excess and four premolars extraction: A case report	
	Zhou YW, Wang YY, He ZF, Lu MX, Li GF, Li H	
1115	Envafolimab combined with chemotherapy in the treatment of combined small cell lung cancer: A case report	
	Liu MH, Li YX, Liu Z	
1122	Thyrotoxicosis in patients with a history of Graves' disease after SARS-CoV-2 vaccination (adenovirus vector vaccine): Two case reports	
	Yan BC, Luo RR	
1129	Administration of modified Gegen Qinlian decoction for hemorrhagic chronic radiation proctitis: A case report and review of literature	
	Liu SY, Hu LL, Wang SJ, Liao ZL	
1137	Surgical resection of a giant thymolipoma causing respiratory failure: A case report	
	Gong LH, Wang WX, Zhou Y, Yang DS, Zhang BH, Wu J	
1144	Successful treatment of granulomatosis with polyangiitis using tocilizumab combined with glucocorticoids: A case report	
	Tang PF, Xu LC, Hong WT, Shi HY	
1152	Langerhans cell histiocytosis misdiagnosed as thyroid malignancy: A case report	
	Shi JJ, Peng Y, Zhang Y, Zhou L, Pan G	
1158	Combined treatment of refractory benign stricture after esophageal endoscopic mucosal dissection: A case report	
	Pu WF, Zhang T, Du ZH	
1165	Bladder preservation in complicated invasive urothelial carcinoma following treatment with cisplatin/gemcitabine plus tislelizumab: A case report	
	Yang R, Chen JX, Luo SH, Chen TT, Chen LW, Huang B	
1175	<i>Nocardia cyriacigeorgica</i> infection in a patient with repeated fever and CD4 ⁺ T cell deficiency: A case report	
	Hong X, Ji YQ, Chen MY, Gou XY, Ge YM	



.	World Journal of Clinical Cases
Conten	ts Thrice Monthly Volume 11 Number 5 February 16, 2023
1182	Closed loop ileus caused by a defect in the broad ligament: A case report
	Zucal I, Nebiker CA
1188	Farly postsurgical lethal outcome due to splenic littoral cell angioma. A case report
1100	lia E Lin H Li VI. Zhang II. Tang I Lu PT. Wang VO. Cui VE. Vang VH Lu ZV
	Jur F, Em 11, El 1E, Zhang JE, Tung E, Eu I 1, Wang 1Q, Cul IF, Tang XII, Eu ZI
1198	Combinations of nerve blocks in surgery for post COVID-19 pulmonary sequelae patient: A case report
	and review of literature
	Jin Y, Lee S, Kim D, Hur J, Eom W
1.0.0	
1206	Incidental right atrial mass in a patient with secondary pancreatic cancer: A case report and review of literature
	Fioretti AM Leopizzi T. La Foraja D. Scicchitano P. Orasta D. Fanizzi A. Massafra P. Oliva S.
	T lorent Ann, Ecopizzi 1, Eu Forgiu D, Scicennano I, Oresie D, Funzzi A, Mussafru R, Onvu S
1217	Difficult airway due to cervical haemorrhage caused by spontaneous rupture of a parathyroid adenoma: A case report
	Han YZ, Zhou Y, Peng Y, Zeng J, Zhao YQ, Gao XR, Zeng H, Guo XY, Li ZQ

Contents

Thrice Monthly Volume 11 Number 5 February 16, 2023

ABOUT COVER

Editorial Board Member of World Journal of Clinical Cases, Tian-Biao Zhou, MD, PhD, Chief Doctor, Professor, Department of Nephrology, Second Affiliated Hospital, Shantou University Medical College, Shantou 515041, Guangdong Province, China. zhoutb@aliyun.com

AIMS AND SCOPE

The primary aim of World Journal of Clinical Cases (WJCC, World J Clin Cases) is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

WJCC mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

INDEXING/ABSTRACTING

The WJCC is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/Science Edition, Current Contents®/Clinical Medicine, PubMed, PubMed Central, Scopus, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 Edition of Journal Citation Reports® cites the 2021 impact factor (IF) for WJCC as 1.534; IF without journal self cites: 1.491; 5-year IF: 1.599; Journal Citation Indicator: 0.28; Ranking: 135 among 172 journals in medicine, general and internal; and Quartile category: Q4. The WJCC's CiteScore for 2021 is 1.2 and Scopus CiteScore rank 2021: General Medicine is 443/826.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Hua-Ge Yu; Production Department Director: Xiang Li; Editorial Office Director: Jin-Lei Wang.

NAME OF JOURNAL World Journal of Clinical Cases	INSTRUCTIONS TO AUTHORS https://www.wignet.com/bpg/gerinfo/204	
ISSN ISSN 2307-8960 (online)	GUIDELINES FOR ETHICS DOCUMENTS https://www.wignet.com/bpg/GerInfo/287	
LAUNCH DATE April 16, 2013	GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH https://www.wignet.com/bpg/gerinfo/240	
FREQUENCY Thrice Monthly	PUBLICATION ETHICS https://www.wjgnet.com/bpg/GerInfo/288	
EDITORS-IN-CHIEF	PUBLICATION MISCONDUCT	
Bao-Gan Peng, Jerzy Tadeusz Chudek, George Kontogeorgos, Maurizio Serati, Ja Hyeon Ku	https://www.wjgnet.com/bpg/gerinfo/208	
EDITORIAL BOARD MEMBERS	ARTICLE PROCESSING CHARGE	
https://www.wjgnet.com/2307-8960/editorialboard.htm	https://www.wjgnet.com/bpg/gerinfo/242	
PUBLICATION DATE	STEPS FOR SUBMITTING MANUSCRIPTS	
February 16, 2023	https://www.wjgnet.com/bpg/GerInfo/239	
COPYRIGHT	ONLINE SUBMISSION	
© 2023 Baishideng Publishing Group Inc	https://www.f6publishing.com	

© 2023 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA E-mail: bpgoffice@wjgnet.com https://www.wjgnet.com



W J C C World Journal C Clinical Cases

World Journal of

Submit a Manuscript: https://www.f6publishing.com

World J Clin Cases 2023 February 16; 11(5): 1165-1174

DOI: 10.12998/wjcc.v11.i5.1165

ISSN 2307-8960 (online)

CASE REPORT

Bladder preservation in complicated invasive urothelial carcinoma following treatment with cisplatin/gemcitabine plus tislelizumab: A case report

Rui Yang, Jun-Xing Chen, Shu-Hang Luo, Ting-Ting Chen, Ling-Wu Chen, Bin Huang

Specialty type: Medicine, research and experimental

Provenance and peer review:

Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): A Grade B (Very good): B Grade C (Good): 0 Grade D (Fair): 0 Grade E (Poor): 0

P-Reviewer: El Tayebi HM, Egypt; Mohammadi S, Iran

Received: November 4, 2022 Peer-review started: November 4, 2022 First decision: December 13, 2022 Revised: December 25, 2022 Accepted: January 20, 2023 Article in press: January 20, 2023

Published online: February 16, 2023



Rui Yang, Jun-Xing Chen, Shu-Hang Luo, Ling-Wu Chen, Bin Huang, Department of Urology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, Guangdong Province, China

Ting-Ting Chen, The Medical Department, 3D Medicines Inc., Shanghai 200120, China

Corresponding author: Bin Huang, MD, PhD, Doctor, Department of Urology, The First Affiliated Hospital of Sun Yat-Sen University, No. 58 Zhong Shan 2nd Road, Guangzhou 510080, Guangdong Province, China. huangb48@mail.sysu.edu.cn

Abstract

BACKGROUND

Invasive urothelial carcinoma (UC) with squamous and glandular differentiation is a highly malignant and complicated pathological subtype, and the standard care is radical cystectomy (RC). However, urinary diversion after RC significantly reduces patient quality of life, thus bladder-sparing therapy has become a research hotspot in this field. Recently, five immune checkpoint inhibitors have been approved for systemic therapy of locally advanced or metastatic bladder cancer by the Food and Drug Administration, but the efficacy of immunotherapy combined with chemotherapy for invasive UC is still unknown, especially for pathological subtypes with squamous and glandular differentiation.

CASE SUMMARY

We report the case of a 60-year-old male who complained of repetitive painless gross hematuria and was diagnosed with muscle-invasive bladder cancer with squamous and glandular differentiation, defined as cT3N1M0 according to the American Joint Committee on Cancer, who had a strong desire to preserve the bladder. Immunohistochemical staining revealed that programmed cell deathligand 1 (PD-L1) expression in the tumor was positive. Thus, a transurethral resection to maximize removal of the bladder tumor was performed under cystoscopy, and the patient subsequently received a combination of chemotherapy (cisplatin/gemcitabine) and immunotherapy (tislelizumab) treatment. No tumor recurrence in the bladder was observed following pathological and imaging examination after 2 cycles and 4 cycles of treatment, respectively. The patient achieved bladder preservation and has been tumor-free for more than two vears.



CONCLUSION

This case shows that the combination of chemotherapy and immunotherapy might be an effective and safe treatment strategy for PD-L1 expression positive UC with divergent histologic differentiation

Key Words: Invasive urothelial carcinoma; Immunotherapy; Chemotherapy; Squamous and glandular differentiation; Tislelizumab; Case report

©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Urothelial carcinoma (UC) with complicated differentiation is highly malignant, and radical cystectomy (RC) is the preferred treatment. Because of the complications related to RC, bladder-sparing therapy has become a research hotspot. We here report a patient who was diagnosed with muscle-invasive bladder cancer with squamous and glandular differentiation and positive programmed cell death-ligand 1 (PD-L1) expression. The patient received a combination of chemotherapy and immunotherapy and achieved bladder preservation and has maintained tumor-free for over two years. This case highlights that the combination treatment might be an effective and safe strategy for UC with divergent histologic differentiation and positive PD-L1 expression.

Citation: Yang R, Chen JX, Luo SH, Chen TT, Chen LW, Huang B. Bladder preservation in complicated invasive urothelial carcinoma following treatment with cisplatin/gemcitabine plus tislelizumab: A case report. World J Clin Cases 2023; 11(5): 1165-1174

URL: https://www.wjgnet.com/2307-8960/full/v11/i5/1165.htm DOI: https://dx.doi.org/10.12998/wjcc.v11.i5.1165

INTRODUCTION

Urothelial carcinoma (UC), originating in the bladder or upper urinary tract, is the most common histological type of cancer[1]. UC has a wide range of clinical and morphological characteristics, including the unique ability to differentiate into all histological variants, including squamous, glandular, micropapillary, sarcomatoid, small cell, clear cell and so on[2]. The biological behavior and treatment strategy of a bladder tumor with variant histology differs from that of conventional UC, which is an uncertain and difficult challenge for clinicians[3]. Although radical cystectomy (RC) is the preferred standard treatment for muscle-invasive bladder cancer (MIBC) according to the National Comprehensive Cancer Network (NCCN), some patients still have a strong desire to preserve the bladder due to the marked decline in quality of life after RC. Unfortunately, effective bladder-sparing treatments are limited.

Platinum-based cytotoxic chemotherapy is the standard treatment for metastatic or locally advanced UC and the preferred treatment option in the perioperative (neoadjuvant and/or adjuvant) setting for MIBC. However, the overall significance of the mixed histological features of MIBC remains unclear. In addition, with the increased understanding of cancer immunobiology, systematic immunotherapy targeting immune checkpoint suppression has been explored and clinically applied in the field of UC[4].

Herein, we report a case of programmed cell death-ligand 1 (PD-L1) expression positive MIBC with squamous and glandular differentiation, who refused total cystectomy. The patient received combination treatment with chemotherapy and immunotherapy after successful transurethral resection of the bladder tumor (TURBT). A marked response to combination treatment was achieved and the patient successfully preserved bladder function.

CASE PRESENTATION

Chief complaints

In August 2020, a 60-year-old male patient was admitted to the Department of Urology of The First Affiliated Hospital of Sun Yat-Sen University (Guangzhou, China) with repetitive painless gross hematuria and a 6-mo history of blood clots.

History of past illness

The patient had no history of chronic respiratory, cardiovascular, or other medical conditions.



Personal and family history

There was no history of genetic disease or UC in his family.

Physical examination

On admission, the patient's temperature was 36.6 °C, heart rate was 70 bpm, respiratory rate was 15 breaths/min, and blood pressure was 136/83 mmHg. The abdomen was soft without masses or organomegaly, and no tenderness or percussed pain was observed at lower abdomen.

Laboratory examinations

Routine blood tests revealed red blood cell, white blood cell, and platelet counts of 4.75×10^{12} /L, 7.47×10^{12} /L, $10^{\circ}/L$, and $229 \times 10^{\circ}/L$, respectively, and hemoglobin level of 147 g/L. Prothrombin and partial thromboplastin times were normal, but the level of fibrinogen was 4.82 g/L (2.00-4.00 g/L). The results of blood biochemistry tests were within normal ranges. Serum creatinine level was 78 μ mol/L and blood urea nitrogen level was 3.9 mmol/L, indicating normal renal function. Routine urine test revealed higher amounts of protein, red blood cells and white blood cells in urine. The electrocardiography and chest X-ray were normal.

Imaging examinations

Pelvic magnetic resonance imaging (MRI) revealed a 24 mm × 42 mm × 29 mm mass located at the posterior wall of the bladder, which invaded the entire muscular layer and the serosa (Figure 1A). Suspicious enlarged lymph nodes adjacent to the left internal iliac vessels in the pelvic cavity were observed (Figure 1B). Cystoscopy and diagnostic TURBT were performed for further examination. Cystoscopy revealed a mass (approximately 45 mm in diameter) at the posterior wall of the bladder, with necrotic tissue and blood clots on the surface (Figure 2A). Pathological examination revealed highgrade invasive UC with squamous and adenoid differentiation (Figure 3A and B), and immunohistochemistry results showed positive expression of some intestinal adenocarcinoma markers. Based on the imaging, pathological and other examinations, the patient was staged as cT3N1M0 according to the American Joint Committee on Cancer.

Further diagnostic work-up

The surgical tumor specimen and paired blood sample obtained from the patient were sent for genetic testing of 733 tumor-related genes (3D Medicines Inc., a College of American Pathologists-accredited and Clinical Laboratory Improvement Amendment-certified laboratory, Shanghai, China). Formalinfixed paraffin-embedded tissue sections were subjected to PD-L1 expression assessment using the VENTANA PD-L1 (SP263) Assay (Roche Diagnostics). PD-L1 expression was also determined using the Tumor Proportion Score (TPS), which is the proportion of viable tumor cells showing partial or complete membrane PD-L1 staining at any intensity. Tumor mutational burden (TMB) was defined as the number of non-synonymous and synonymous somatic single nucleotide variations and indels in the examined coding regions, excluding driver mutations.

Next generation sequencing results revealed that the tumor harbored six somatic mutations: ERBB2 p.S310F, RB1 p.F404Lfs*6, ARID1A p.S733*, TERT c.-124C>T, TP53 p.R282W and TP53 p.P152T (Table 1). Immunohistochemical (IHC) staining revealed that PD-L1 expression in the tumor was positive (TPS = 30%, Figure 3C). The microsatellite status was stable and the TMB was classified as intermediate with 10.06 mutations per megabase, which was less than 51% of MIBCs in the detection database (Figure 4).

FINAL DIAGNOSIS

The patient was preliminarily diagnosed with MIBC, whose pathological type was complicated UC with squamous and glandular differentiation.

TREATMENT

RC is the preferred choice of treatment for UC. However, the patient strongly wished to preserve the bladder. We decided to administer preoperative neoadjuvant chemotherapy first, and evaluate whether RC should be performed according to the treatment effect. The standard treatment of preoperative neoadjuvant chemotherapy for MIBC is platinum-based cytotoxic chemotherapy, but the benefits in this complicated pathological type are unknown. In addition, IHC testing of tumor tissue showed that PD-L1 expression was positive, indicating that the patient might benefit from immunotherapy. Considering the high treatment efficacy of anti-programmed cell death-1 (PD-1) immunotherapy for MIBC and the patient's circumstances, he subsequently received chemotherapy combined with immunotherapy for bladder-sparing therapy. TURBT was performed to remove as much tumor tissue as possible, with the operative wound in the serosal layer of the bladder. The patient then received immunotherapy (tislel-



Yang R et al. Bladder preservation in invasive urothelial carcinoma

Table 1 The somatic mutations				
Gene	Mutation	Abundance		
ERBB2	p.S310F	3.62%		
RB1	p.F404Lfs*6	10.42%		
ARID1A	p.S733*	11.14%		
TERT	c124C>T	14.83%		
TP53	p.R282W	3.70%		
	<i>p.P</i> 152 <i>T</i>	24.48%		

izumab) combined with chemotherapy (cisplatin/gemcitabine) every three weeks for four cycles. Cisplatin was administered at 70 mg/m² intravenously from the second day of the three-week cycle, gemcitabine was administered at 1000 mg/m² intravenously on day one and eight every three weeks and tislelizumab was administered 200 mg intravenously on day one of the three-week cycle.

Side effects during the treatment period included low-grade anemia, leukopenia and subclinical hypothyroidism. To evaluate the efficacy of immunotherapy combined with chemotherapy, the patient underwent pelvic MRI, cystoscopy and TURBT after two cycles of therapy. Pelvic MRI revealed no obvious nodules or masses on the posterior wall of the bladder and no enlarged lymph nodes around the iliac vessels (Figure 1C and D). Cystoscopy showed that the primary tumor site had been replaced by scar tissue (Figure 2B). The tissue sample collected during cystoscopy for pathological and IHC analysis showed no malignant characteristics. After four cycles of combination therapy, MRI demonstrated that there were still no nodules or masses in the bladder and the lymph nodes were the same as previously described (Figure 1E and F). Full-body positron emission tomography/computed tomography showed that the lesion described previously was obviously reduced without evidence of distant metastasis. Pathological examination results were also negative. All results indicated a marked response following the combination of chemotherapy and immunotherapy; thus, the next treatment strategy developed was immunotherapy, where tislelizumab was administered 200 mg intravenously on day one of the three-week cycle alone.

OUTCOME AND FOLLOW-UP

The patient was advised to undergo MRI or cystoscopy every three months for the first year and every six months for the next two years to assess his condition.

The entire treatment period was two years, the patient was reexamined by MRI, and there was no recurrence of the tumor or enlarged lymph nodes (Figure 1G and H), which indicated that the patient was tumor-free with preserved bladder for almost two years. The overall treatment timeline is shown in Figure 5.

DISCUSSION

Bladder cancer is one of the most common malignant neoplasms worldwide. More than 90% of these cancers are transitional cell carcinomas, which can also present mixed with other malignant components [5]. The mixed type of bladder histology includes squamous differentiation (20%-60% of bladder cancers), adenocarcinoma or glandular differentiation (10%), sarcomatoid (7%), micropapillary (3.7%), and lymphoepithelioma-like carcinoma^[2]. Thus, the identification of a histological variant type in UC is essential, which may be associated with different clinical outcomes and treatment strategies [6,7]. Herein, we report a case of PD-L1 positive invasive UC with squamous and glandular differentiation. Considering the patient's strong desire for bladder preservation, bladder-sparing therapy with the combination of cisplatin/gemcitabine and tislelizumab was administered after TURBT. A marked response with no tumor or malignant features was observed following imaging and pathological examinations. Several studies have reported that the clinical phenotype of squamous and glandular differentiation was different to pure pathological types of UC. Adenocarcinoma is thought to have a poorer prognosis but has not been adequately studied to make definitive statements[8]. It has been shown that pure adenocarcinoma is relatively resistant to chemotherapy and radiation, and there is no evidence that these treatments are beneficial in mixed tumors[9]. Besides, the significance of invasive UC with squamous and glandular differentiation at TURBT is still not confirmed, meaning no satisfactory and effective treatment has been found for this pathological type of UC[10]. However, research on a series of patients with variant histology found that UC with squamous or glandular or





DOI: 10.12998/wjcc.v11.i5.1165 Copyright ©The Author(s) 2023.

Figure 1 Pelvic magnetic resonance imaging during different treatment stages. A: Tumor site before treatment; B: Lymph node before treatment; C: Tumor site after 2 cycles of treatment; D: Lymph node after 2 cycles of treatment; E: Tumor site after 4 cycles of treatment; F: lymph node after 4 cycles of treatment; G: Tumor site after 2 yr of treatment; H: Lymph node after 2 yr of treatment.

> both types of differentiation often present with a higher pathologic stage, and significantly longer overall survival with cisplatin-based neoadjuvant chemotherapy (P = 0.024)[11].

> Although RC is the standard treatment for MIBC, some patients have a strong desire to preserve their native bladders due to poor quality of life after RC. Other treatment options for these patients are chemoradiotherapy or radiotherapy. In the present patient, the bladder tumor was relatively small with a maximum diameter of 42 mm. Radiotherapy will inevitably irradiate normal tissue, leading to adverse events such as gastrointestinal reactions, radioactive cystitis, skin damage, and some systemic side effects. In addition, RC is an alternative in the case of failed drug treatment, and the side effects of radiotherapy have great effects on the surgery. The effects of radiotherapy on operating room tissue can also cause fibrosis, which leads to fixation of pelvic organs, making blunt dissection more difficult, and causes disruption of surgical landmarks and loss of tissue planes[12,13]. Postoperative complications such as intestinal obstruction, poor wound healing, ureteral ileal anastomotic leakage and stenosis, lymphatic leakage, lower extremity venous embolism and cardiopulmonary, liver and kidney dysfunction can also increase. Some studies revealed that the rate of one or more complications in patients with RC and a history of pelvic radiotherapy is as high as 48%-76%, which is significantly higher than that in patients without a history of pelvic radiotherapy (25.5%-35.8%)[13,14]. In other studies, the perioperative mortality (0.8%) of RC in patients without a history of pelvic radiotherapy







DOI: 10.12998/wjcc.v11.i5.1165 **Copyright** ©The Author(s) 2023.

Figure 2 Cystoscopy. A: Cystoscopy before treatment; B: Cystoscopy after 2 cycles of treatment.

was lower than that (5.7%) in patients with a history of pelvic radiotherapy [14,15]. Overall, radiotherapy was not considered the preferred treatment option for this patient.

PD-1/PD-L1 blockade has been approved as a promising and effective treatment option for patients with advanced stage UC, and PD-L1 IHC expression has been shown to be involved in predicting immune checkpoint inhibitor therapy efficacy[1]. Five different anti-PD-1 (durvalumab, nivolumab and pembrolizumab) or anti-PD-L1 antibodies (atezolizumab and avelumab) have currently been approved for treatment of locally advanced or metastatic UC as second-line post-platinum-based chemotherapy, including atezolizumab[16] or pembrolizumab[17] and may be considered for cisplatin ineligible patients as first-line therapy if PD-L1 expression is positive. Moreover, in a single-arm phase 2 trial (NCT04004221/CTR20170071), tislelizumab (anti-PD-1 monoclonal antibody) as second-line therapy in PD-L1 positive (SP263) UC patients who progressed during/following platinum-containing therapy and had no prior PD-1/L1 inhibitor treatment achieved a confirmed objective response rate of 24% in 104 evaluable patients, including 10 complete and 15 partial responses. Median progression-free survival and overall survival were 2.1 and 9.8 mo, respectively[18].

Different genetic mutations can influence immunotherapy efficacy. Six somatic mutations in our patient, including ERBB2 p.S310F, RB1 p.F404Lfs*6, ARID1A p.S733*, TERT c.-124C>T, TP53 p.R282W, and TP53 p.P152T, were considered tumorigenic. ERBB2 encodes an epidermal growth factor receptor, and its amplification can regulate cell growth by activating downstream signaling pathways[19]. A phase 2 trial showed that 18 patients with lung cancer carrying ERBB2 mutations were treated with trastuzumab emtansine (T-DM1), with an overall response rate of 44% and a median progression free survival of 5 mo^[20] Cells carrying the S310F mutation are sensitive to the ERBB2 inhibitor and ERBB2 monoclonal antibody^[21]. However, there have been few studies on the other somatic mutations as biomarkers for the treatment of UC.

TMB can be used as a marker for evaluating the effects of immunotherapy. Tumor cells with higher TMB are more easily recognized by the immune system and may have a stronger immune response to checkpoint inhibitors. In a clinical study, patients with non-small cell lung cancer were divided into high and low TMB groups according to the median TMB, and the clinical benefit rates of the high and low TMB groups receiving pembrolizumab were 73% and 13% in the discovery cohorts, 83% and 22% in the validation cohorts^[22]. Additionally, the TMB of melanoma patients who received ipilimumab and achieved long-term clinical benefits was significantly higher than that of melanoma patients who did





DOI: 10.12998/wjcc.v11.i5.1165 Copyright ©The Author(s) 2023.

Figure 3 Histology of the tumor tissue before treatment. A and B: Representative images show mixed histology of (A) adenocarcinoma and (B) glandular variants by H&E staining (6 × magnification); C: Immunohistochemistry for programmed cell death-ligand 1 expression in bladder cancer tissues (200 × magnification).

not achieve long-term clinical benefits^[23].

In the present case, considering that PD-L1 IHC staining of tumor tissue was positive, the somatic mutation of ERBB2 p.S310F, and 51% TMB, a combination of chemotherapy and immunotherapy was finally chosen.

There are some limitations in this study. As the patient had a strong desire for bladder preservation, he did not undergo RC as the initial treatment which is recommended by the NCCN. Pathological specimens used for efficacy assessment were obtained by TURBT and thus there was possible undetected tumor tissue. Therefore, the pathology and follow-up results should be combined to comprehensively evaluate the treatment efficacy. In addition, the Food and Drug Administration has currently approved various PD-L1 assays for clinical use, usually corresponding to specific immune checkpoint inhibitors[24].

Analyses of the same sample using different assays may lead to discordant results, which might influence clinical treatment decisions. Furthermore, assuming that the cut-off value of the PD-L1 score applied in clinical trials is intended to achieve statistically predefined results, it may not reflect a uniform tumor biological state[7].

For accurate analysis, we reviewed a series of previous studies, based on PD-L1 assays (SP263) and cut-off values (TPS \geq 25%) that were used in clinical trials of tislelizumab, and applied them to our case [18,25]. Furthermore, to minimize manual error, automated quantification and interpretation of the PD-L1 IHC results were adopted in this case.

CONCLUSION

We report a case of invasive UC with squamous and glandular differentiation and positive PD-L1 expression, for which there is currently no established therapy for such differentiation types. The tumor showed a marked response to the treatment with the combination of cisplatin/gemcitabine and tislelizumab, and the patient's bladder was successfully preserved. This case provides a new strategy for the treatment of patients with complex mixed histology MIBC. The combination of immunotherapy and chemotherapy for MIBC patients with positive PD-L1 expression may postpone the time to complete





Figure 4 Tumor mutational burden in the patient. TMB: Tumor mutational burden.





Figure 5 Timeline of patient treatment. TURBt: Transurethral resection of the bladder tumor; IHC: Immunohistochemical; MRI: Pelvic magnetic resonance imaging.

bladder resection and improve patient quality of life.

FOOTNOTES

Author contributions: Huang B contributed to conceptualization; Chen JX and Chen LW conducted the investigation; Yang R prepared the original draft; Luo SH wrote and reviewed the manuscript; Yang R and Chen TT edited the manuscript; All authors have read the article and approved the submitted version.

Informed consent statement: Written informed consent was obtained from the patient for the publication of any potentially identifiable images or data included in this article.

Conflict-of-interest statement: Author Ting-Ting Chen was employed by the company 3D Medicines Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

CARE Checklist (2016) statement: The authors have read CARE Checklist (2016), and the manuscript was prepared and revised according to CARE Checklist (2016).

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is noncommercial. See: https://creativecommons.org/Licenses/by-nc/4.0/



Country/Territory of origin: China

ORCID number: Jun-Xing Chen 0000-0002-7264-5110; Shu-Hang Luo 0000-0002-9992-0530; Ling-Wu Chen 0000-0001-6356-5648; Bin Huang 0000-0002-6429-4023.

S-Editor: Li L L-Editor: A P-Editor: Li L

REFERENCES

- Lenis AT, Lec PM, Chamie K, Mshs MD. Bladder Cancer: A Review. JAMA 2020; 324: 1980-1991 [PMID: 33201207 1 DOI: 10.1001/jama.2020.17598]
- 2 Shanks JH, Iczkowski KA. Divergent differentiation in urothelial carcinoma and other bladder cancer subtypes with selected mimics. Histopathology 2009; 54: 885-900 [PMID: 19178589 DOI: 10.1111/j.1365-2559.2008.03167.x]
- 3 Willis DL, Porten SP, Kamat AM. Should histologic variants alter definitive treatment of bladder cancer? Curr Opin Urol 2013; 23: 435-443 [PMID: 23880739 DOI: 10.1097/MOU.0b013e328363e415]
- Kim HS, Seo HK. Immune checkpoint inhibitors for urothelial carcinoma. Investig Clin Urol 2018; 59: 285-296 [PMID: 30182073 DOI: 10.4111/icu.2018.59.5.285]
- Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet 2009; 374: 239-249 [PMID: 19520422 DOI: 10.1016/S0140-6736(09)60491-8
- Amin MB. Histological variants of urothelial carcinoma: diagnostic, therapeutic and prognostic implications. Mod Pathol 6 2009; 22 Suppl 2: S96-S118 [PMID: 19494856 DOI: 10.1038/modpathol.2009.26]
- 7 Kim B, Lee C, Kim YA, Moon KC. PD-L1 Expression in Muscle-Invasive Urinary Bladder Urothelial Carcinoma According to Basal/Squamous-Like Phenotype. Front Oncol 2020; 10: 527385 [PMID: 33365265 DOI: 10.3389/fonc.2020.527385]
- Black PC, Brown GA, Dinney CP. The impact of variant histology on the outcome of bladder cancer treated with curative 8 intent. Urol Oncol 2009; 27: 3-7 [PMID: 18367107 DOI: 10.1016/j.urolonc.2007.07.010]
- 9 Pons F, Orsola A, Morote J, Bellmunt J. Variant forms of bladder cancer: basic considerations on treatment approaches. Curr Oncol Rep 2011; 13: 216-221 [PMID: 21360040 DOI: 10.1007/s11912-011-0161-4]
- 10 Daneshmand S, Nazemi A. Neoadjuvant Chemotherapy in Variant Histology Bladder Cancer: Current Evidence. Eur Urol Focus 2020; 6: 639-641 [PMID: 32451316 DOI: 10.1016/j.euf.2020.04.011]
- 11 Mitra AP, Bartsch CC, Bartsch G Jr, Miranda G, Skinner EC, Daneshmand S. Does presence of squamous and glandular differentiation in urothelial carcinoma of the bladder at cystectomy portend poor prognosis? Urol Oncol 2014; 32: 117-127 [PMID: 23477878 DOI: 10.1016/j.urolonc.2012.08.017]
- 12 Kim HL, Steinberg GD. Complications of cystectomy in patients with a history of pelvic radiation. Urology 2001; 58: 557-560 [PMID: 11597538 DOI: 10.1016/s0090-4295(01)01269-9]
- 13 Ramani VA, Maddineni SB, Grey BR, Clarke NW. Differential complication rates following radical cystectomy in the irradiated and nonirradiated pelvis. Eur Urol 2010; 57: 1058-1063 [PMID: 20022162 DOI: 10.1016/j.eururo.2009.12.002]
- Chang SS, Cookson MS, Baumgartner RG, Wells N, Smith JA Jr. Analysis of early complications after radical cystectomy: 14 results of a collaborative care pathway. J Urol 2002; 167: 2012-2016 [PMID: 11956429 DOI: 10.1016/S0022-5347(05)65074-4
- 15 Novotny V, Hakenberg OW, Wiessner D, Heberling U, Litz RJ, Oehlschlaeger S, Wirth MP. Perioperative complications of radical cystectomy in a contemporary series. Eur Urol 2007; 51: 397-401; discussion 401 [PMID: 16905242 DOI: 10.1016/j.eururo.2006.06.014]
- 16 Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, Dawson NA, van der Heijden MS, Dreicer R, Srinivas S, Retz MM, Joseph RW, Drakaki A, Vaishampayan UN, Sridhar SS, Quinn DI, Durán I, Shaffer DR, Eigl BJ, Grivas PD, Yu EY, Li S, Kadel EE 3rd, Boyd Z, Bourgon R, Hegde PS, Mariathasan S, Thåström A, Abidoye OO, Fine GD, Bajorin DF; IMvigor210 Study Group. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 2017; 389: 67-76 [PMID: 27939400 DOI: 10.1016/S0140-6736(16)32455-2]
- 17 Balar AV, Castellano D, O'Donnell PH, Grivas P, Vuky J, Powles T, Plimack ER, Hahn NM, de Wit R, Pang L, Savage MJ, Perini RF, Keefe SM, Bajorin D, Bellmunt J. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol 2017; 18: 1483-1492 [PMID: 28967485 DOI: 10.1016/S1470-2045(17)30616-2]
- 18 Ni K, Wang Z, Yu S, Zheng J, Li G. Camrelizumab monotherapy leading to partial remission for relapsed upper tract urothelial carcinoma after radical nephroureterectomy: a case report. Transl Androl Urol 2021; 10: 1821-1826 [PMID: 33968671 DOI: 10.21037/tau-21-268]
- Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005; 5: 341-354 19 [PMID: 15864276 DOI: 10.1038/nrc1609]
- Li BT, Shen R, Buonocore D, Olah ZT, Ni A, Ginsberg MS, Ulaner GA, Offin M, Feldman D, Hembrough T, Cecchi F, 20 Schwartz S, Pavlakis N, Clarke S, Won HH, Brzostowski EB, Riely GJ, Solit DB, Hyman DM, Drilon A, Rudin CM, Berger MF, Baselga J, Scaltriti M, Arcila ME, Kris MG. Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial. J Clin Oncol 2018; 36: 2532-2537 [PMID: 29989854 DOI: 10.1200/JCO.2018.77.9777
- Greulich H, Kaplan B, Mertins P, Chen TH, Tanaka KE, Yun CH, Zhang X, Lee SH, Cho J, Ambrogio L, Liao R, 21



Imielinski M, Banerji S, Berger AH, Lawrence MS, Zhang J, Pho NH, Walker SR, Winckler W, Getz G, Frank D, Hahn WC, Eck MJ, Mani DR, Jaffe JD, Carr SA, Wong KK, Meyerson M. Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc Natl Acad Sci USA 2012; 109: 14476-14481 [PMID: 22908275 DOI: 10.1073/pnas.1203201109]

- 22 Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, Miller ML, Rekhtman N, Moreira AL, Ibrahim F, Bruggeman C, Gasmi B, Zappasodi R, Maeda Y, Sander C, Garon EB, Merghoub T, Wolchok JD, Schumacher TN, Chan TA. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015; 348: 124-128 [PMID: 25765070 DOI: 10.1126/science.aaa1348]
- Chan TA, Wolchok JD, Snyder A. Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma. N Engl J Med 23 2015; 373: 1984 [PMID: 26559592 DOI: 10.1056/NEJMc1508163]
- 24 Doroshow DB, Bhalla S, Beasley MB, Sholl LM, Kerr KM, Gnjatic S, Wistuba II, Rimm DL, Tsao MS, Hirsch FR. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol 2021; 18: 345-362 [PMID: 33580222 DOI: 10.1038/s41571-021-00473-5]
- Gulinac M, Dikov D, Velikova T, Belovezhdov V. Increased PD-L1 expression in high-grade bladder cancer with 25 squamous cell differentiation in Bulgarian and French patients' samples. Ann Diagn Pathol 2020; 49: 151640 [PMID: 33069081 DOI: 10.1016/j.anndiagpath.2020.151640]





Published by Baishideng Publishing Group Inc 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA Telephone: +1-925-3991568 E-mail: bpgoffice@wjgnet.com Help Desk: https://www.f6publishing.com/helpdesk https://www.wjgnet.com

